In fact, many people find that the benefits of tirzepatide, such as improved blood sugar control and weight loss, outweigh the mild and temporary side effects
DOI: [2] Laukkanen T, Kunutsor SK, Khan H, Zaccardi F, Laukkanen JA
The pipeline is full, and everyone's treating this like an unqualified win for obesity medicine
The combined electrophysiological analysis further shows an overall reduction in functional expression of NR2A subunits along with relative increases in both, contribution of NR2B to the synaptic and extrasynaptic NMDAR-mediated currents and the magnitude of extrasynaptic NMDAR-mediated currents in lesioned HMNs
So, this is not a unique situation also, Ben, just for these two drugs of Eliquis and Xarelto, I truly believe that every other MFP drug will have significant issues with regards to access because of this increasing out of pocket costs that will occur because PBMs are going to fill the pressure of filling the void from the profitability that theyre going to lose
They compared them with similar patients who took DPP-4 inhibitors, another class of diabetes drugs
